A comparison of preference assessment instruments used in a clinical trial: Responses to the visual analog scale from the EuroQol EQ-5D and the health utilities index

被引:38
作者
Glick, HA
Polsky, D
Willke, RJ
Schulman, KA
机构
[1] Univ Penn, Div Gen Internal Med, Philadelphia, PA 19104 USA
[2] Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA
[3] Pharmacia & Upjohn Inc, Kalamazoo, MI 49001 USA
[4] Georgetown Univ, Med Ctr, Div Gen Internal Med, Clin Econ Res Unit, Washington, DC 20007 USA
关键词
preference assessment; health utilities index; EuroQol; clinical trials; subarachnoid hemorrhage;
D O I
10.1177/0272989X9901900305
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Objectives. To compare preference assessments that were made by using the EuroQol EQ-5D and the Health Utilities Index Mark II. Subjects. 561 patients in a randomized trial of tirilazad mesylate for aneurysmal subarachnoid hemorrhage. Measures. Three preference assessments (a value score for the EuroQol instrument and value and utility scores for the Health Utilities Index) made three months after randomization. The averages for each of the three scores, stratified by clinical outcomes and attributes of the Health Utilities Index health status classification system, were compared. To evaluate potential sources of difference between the instruments, the authors estimated two alternative Health Utilities Index scoring rules that were based on patient responses to the EuroQol instrument. Results. Patients' ratings of their current health made by using the 100-point visual analog scale from the EuroQol instrument were more similar to the utility scores for the Health Utilities Index than they were to the value scores for the Health Utilities index. The biggest differences between the visual analog scores for the EuroQol instrument and the utility scores for the Health Utilities index were seen at higher levels of functioning. Conclusion. For states representing higher levels of functioning, differences were seen between patients' self-ratings obtained by using the EuroQol instrument and the patients' utility scores on the Health Utilities Index; for states representing lower levels of functioning, substantial agreement was observed between these two scores. Differences observed at the higher levels of functioning suggest that further research is needed to determine whether the Health Utility Index's assignment of a score of 1.0 to the reference state representing being healthy is appropriate.
引用
收藏
页码:265 / 275
页数:11
相关论文
共 34 条
[1]  
[Anonymous], 1988, Nonlinear Preference and Utility Theory
[2]   WEIGHTS FOR SCORING THE QUALITY OF WELL-BEING INSTRUMENT AMONG RHEUMATOID ARTHRITICS - A COMPARISON TO GENERAL-POPULATION WEIGHTS [J].
BALABAN, DJ ;
SAGI, PC ;
GOLDFARB, NI ;
NETTLER, S .
MEDICAL CARE, 1986, 24 (11) :973-980
[3]  
BERTHELOT JM, 1993, COLLOQ INSE, V226, P161
[4]   THE USE OF FEMALE SPOUSE PROXIES IN COMMON SYMPTOM REPORTING [J].
CLARRIDGE, BR ;
MASSAGLI, MP .
MEDICAL CARE, 1989, 27 (04) :352-366
[5]   Are proxy assessments of health status after stroke with the EuroQol questionnaire feasible, accurate, and unbiased? [J].
Dorman, PJ ;
Waddell, F ;
Slattery, J ;
Dennis, M ;
Sandercock, P .
STROKE, 1997, 28 (10) :1883-1887
[6]   Dollars may not buy as many QALYs as we think: A problem with defining quality-of-life adjustments [J].
Fryback, DG ;
Lawrence, WF .
MEDICAL DECISION MAKING, 1997, 17 (03) :276-284
[7]   Economic analysis of tirilazad mesylate for aneurysmal subarachnoid hemorrhage - Economic evaluation of a phase III clinical trial in Europe and Australia [J].
Glick, H ;
Willke, R ;
Polsky, D ;
Llana, T ;
Alves, WM ;
Kassell, N ;
Schulman, K .
INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE, 1998, 14 (01) :145-160
[8]  
GOLD MR, 1996, COST EFFECTIVENESS H, P124
[9]   LARGE-SCALE HEALTH OUTCOMES EVALUATION - HOW SHOULD QUALITY-OF-LIFE BE MEASURED .1. CALIBRATION OF A BRIEF QUESTIONNAIRE AND A SEARCH FOR PREFERENCE SUBGROUPS [J].
HADORN, DC ;
UEBERSAX, J .
JOURNAL OF CLINICAL EPIDEMIOLOGY, 1995, 48 (05) :607-618
[10]   A randomized, double-blind, vehicle-controlled trial of tirilazad mesylate in patients with aneurysmal subarachnoid hemorrhage: A cooperative study in North America [J].
Haley, EC ;
Kassell, NF ;
AppersonHansen, C ;
Maile, MH ;
Alves, WM .
JOURNAL OF NEUROSURGERY, 1997, 86 (03) :467-474